CTLA4 and metastatic melanoma: Most recently the five-year results from the Phase 3 CheckMate 067 clinical trial for metastatic melanoma showed a five-year overall survival rate of 52% for patients that received dual anti-CTLA-4 and anti-PD-1 therapy compared to 26% and 44% (respectively) for single CPI therapy [48].